Business
Cardiff Oncology Announces Upcoming Poster Presentations at the AACR Annual Meeting
SAN DIEGO, March 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop
About this update from Cardiff Oncology, Inc.
[{"type":"text","content":"SAN DIEGO, March 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the publication of two abstracts that have been accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans, Louisiana from April 8-13, 2022.\n\n \n \n \n \n \n \n\n \nThe full texts of the published abstracts can be found on the AACR Annual Meeting website. Details on the corresponding posters are shown below.\nPoster Title:\nBiomarkers of response to abiraterone and the polo-like kinase 1 (PLK1) inhibitor onvansertib in metastatic castration resistant prostate cancer (mCRPC) patients\nSession Title:\nBiomarkers Predictive of Therapeutic Benefit 1\nSession Date:\nApril 11, 2022\nSession Start Time:\n9:00 AM CT\nLocation:\nPoster Section 30\nThis abstract describes genomic and transcriptomic analyses from the ongoing Phase 2 trial of onvansertib in combination with Zytiga® (abiraterone)/prednisone in mCRPC patients with early abiraterone resistance. Collectively, these analyses suggest that alterations in PTEN and MTOR, two key genes of the PI3K signaling pathway, are potential biomarkers for sensitivity to onvansertib-abiraterone combination therapy in mCRPC patients with early abiraterone-resistance.\nPoster Title:\nCombining PARP inhibition with the polo-like kinase 1 (PLK1) inhibitor onvansertib overcomes PARP inhibitor resistance\nSession Title:\nDrug Resistance and Reversal of Resistance\nSession Date:\nApril 12, 2022\nSession Start Time:\n1:30 PM CT\nLocation:\nPoster Section 22\nThis abstract includes preclinical data that demonstrate the potent anti-tumor activity of onvansertib combined with the PARP inhibitor olaparib in olaparib-resistant ovarian cancer models. Additional preclinical studies are ongoing to further assess the potential of the onvansertib-olaparib combination in models of ovarian, prostate, pancreatic and breast cancer. \nAbout Cardiff Oncology, Inc.Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is the third generation PLK1 inhibitor ...